Message from the President
Unwaveringly committed to quality manufacturing, we will always offer top-grade, reasonably priced, therefore highly reliable pharmaceuticals to contribute to the world, through our efforts to enhance the quality and productivity.
FUJIFILM KYOWA KIRIN BIOLOGICS was launched in March 2012 to develop and meet the global demand for biosimilars, also known as subsequent entry biologics. Due to the particular requirements of biopharmaceuticals, development requires specialized expertise and know-hows, while production demands the use of advanced techniques and facilities. The combination of the technology and know-hows that have been accumulated by Kyowa Hakko Kirin through its R&D and productions in the biomedical field, and the engineering, manufacturing, quality-management and analytical skills that have been honed by Fujifilm Corporation through its wide-ranging businesses, has enabled us to achieve a top level of quality and create an innovative production process that will reduce the production costs.
Healthcare costs have risen recently, particularly in developed countries, due to ageing populations and the emergence of highly effective, yet highly expensive, medicines such as biopharmaceuticals. These rising costs are a burden on those countries’ finances. As the situation is likely to escalate in the future, we hope to contribute to containing rising healthcare costs by making biosimilars available as less-pricey biopharmaceuticals.
In 2016, our first product, an adalimumab biosimilar (development code number: FKB327), successfully met the prespecified criteria of the primary endpoints in the phase-III global clinical trial, while our second product, a bevacizumab biosimilar (development code number: FKB238), entered its phase-III global clinical trial.
We will continue to commit all our effort to promptly provide superior quality products at the lowest possible cost, always considering those patients who shall be using them. We are committed to continuously advancing the development of biosimilars so we can deliver them as early as possible to the right patients. We greatly appreciate your continued support and encouragement in our ongoing mission.
Hideaki Nomura,President & CEO